Sep 5, 2026
2:00 PM12:00 PM
ePoster display
PD600 - EARLY REAL-WORLD CHANGES IN ANTHROPOMETRY, QUALITY OF LIFE AND LIFESTYLE HABITS IN ADULTS WITH OBESITY TREATED WITH GLP-1-BASED THERAPY
PD600
EARLY REAL-WORLD CHANGES IN ANTHROPOMETRY, QUALITY OF LIFE AND LIFESTYLE HABITS IN ADULTS WITH OBESITY TREATED WITH GLP-1-BASED THERAPY
E. Delgado Garcia1,2,3,*, M. Sanchez Ibañez1,2,3, M. Nieto De la Marca1,3,4, S. Del Amo Simon1,2,3, R. Jimenez Sahagun1,2,3, G. Diaz Soto1,2,3, E. Gomez Hoyos1,2,3, J. J. Lopez Gomez1,2,3, D. De Luis Roman1,3,4 on behalf of IBioVall (investigación biosanitaria, traslación, talento) Valladolid, Spain
1Endocrinologia y Nutricion, Hospital Clinico Universitario , 2Centro de Investigación de Endocrinología y Nutrición Clínica, IENVA, 3investigación biosanitaria, traslación, talento, IBioVall, 4investigación biosanitaria, traslación, talento, IENVA, Valladolid, Spain
Rationale: Real-world data on early lifestyle and patient-reported changes during anti-obesity treatment with glucagon-like peptide-1 (GLP-1)-based therapies remain limited. We evaluated short-term changes in anthropometry, weight-related quality of life and lifestyle habits in adults with obesity treated in routine clinical practice.
Methods: Prospective observational study in non-diabetic adults with body mass index (BMI) >27 kg/m² plus cardiovascular risk factors or >30 kg/m² treated with GLP-1-based therapy in an endocrinology unit. Assessments were performed at baseline, 1 month and 3 months. Weight, BMI, waist and hip circumferences, weight-related quality of life, Mediterranean diet adherence and physical activity were analysed using paired parametric tests.
Results: Eighty-two patients were included (age 46.4±11.4 years; 78% women; baseline BMI 39.5±6.0 kg/m²). At 3 months, mean weight decreased by 10.3±4.0 kg (p<0.001), waist circumference by 10.1±6.1 cm (p<0.001), and hip circumference by 8.4±7.2 cm (p<0.001). Weight-related quality of life improved by 12.7±8.8 points (p<0.001). Mediterranean diet adherence increased from 7.9±1.9 to 8.7±2.1 points (p=0.013), weekly moderate-intensity activity days from 0.9±1.7 to 1.8±2.3 (p=0.007), and days with walking ≥10 minutes from 4.4±2.7 to 5.2±2.1 (p=0.011).
Conclusion: : In routine clinical practice, GLP-1-based therapy was associated with clinically meaningful short-term improvements in anthropometric measures and weight-related quality of life in adults with obesity, together with modest favourable changes in Mediterranean diet adherence and physical activity habits.
Disclosure of Interest: None declared